Morphic Shows Potential For An ‘Oral Entyvio’ With Phase IIa Data

 
• By Joseph Haas

MORF-057, addressing the same target as Takeda blockbuster Entyvio, shows efficacy and safety in ulcerative colitis. Various companies have sought an oral competitor to established biologics in UC.

Biz competition
Morphic made progress in the race for an oral therapy in UC • Source: Shutterstock

More from Clinical Trials

More from R&D